16 May 2023 Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
16 May 2023 Sony and Astellas Enter into Collaborative Research Agreement to Discover a Novel ADC Platform for the Oncology Field
15 May 2023 Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic
15 May 2023 BiOneCure Therapeutics and Nanjing Leads Biolabs Join Forces to Develop Innovative Anti-Drug Conjugates (ADCs) for Solid Tumor Treatment
15 May 2023 U.S. Food and Drug Administration Issues Complete Response Letter for Byondis' [Vic-]Trastuzumab Duocarmazine
15 May 2023 Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
15 May 2023 Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program
13 May 2023 LaNova Medicines Announces Global Exclusive License Agreement with AstraZeneca for LM-305, a Novel GPRC5D-Targeting Antibody Drug Conjugate
12 May 2023 Results of Phase I Clinical Study of Qilu Pharma's PD-1/CTLA-4 Bifunctional Antibody Iparomlimab/Tuvonralimab Published Online in Journal of Hematology & Oncology
10 May 2023 Ultomiris approved in the EU for adults with neuromyelitis optica spectrum disorder (NMOSD)
10 May 2023 Sandoz strengthens pipeline expansion through partnership to develop and manufacture multiple biosimilars
10 May 2023 Lassen Therapeutics Announces Oral Presentation of Phase I Data of LASN01, an IL-11 Receptor-Blocking Antibody for Treatment of Pulmonary Fibrosis, at the American Thoracic Society 2023 Annual Meeting
10 May 2023 Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases
10 May 2023 Summit Therapeutics Announces First Patient Treated in Phase III HARMONi Clinical Trial Evaluating Ivonescimab (SMT112)
09 May 2023 Arxx Therapeutics initiates first-in-human trial of AX-202 – a monoclonal antibody under development for fibrotic diseases
09 May 2023 ProMIS Neurosciences Announces FDA Clearance of Investigational New Drug (IND) Application for PMN310 in Alzheimer’s Disease
09 May 2023 FibroGen Enters into Exclusive License for FOR46 with Fortis Therapeutics
09 May 2023 Biosion Presents Discovery and Development Data at PEGS for its Anti-CD40 Agonistic Antibody
09 May 2023 Innovent Announces First Participant Dosed in Phase 3 Study (RESTORE) of IBI311 (Anti-IGF-1R Monoclonal Antibody) in Patients with Thyroid Eye Disease
09 May 2023 Hummingbird Bioscience to Present Preclinical Proof of Concept for Potentially First-In-Class Antibody Targeting Autoimmune Diseases
09 May 2023 FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
08 May 2023 Eisai enters into joint development agreement with BlissBio for antibody drug conjugate BB-1701 with option rights for strategic collaboration
05 May 2023 Trellis Bioscience Announces Positive Interim Phase 1 Results for TRL1068, a Novel Native Human Monoclonal Antibody Which Reduces Bacterial Biofilm Burden in Chronic Prosthetic Joint Infections
05 May 2023 Alvotech Initiates Confirmatory Patient Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
05 May 2023 Tonix Pharmaceuticals Announces IND Clearance for TNX-1500 (anti-CD40L mAb) for the Prevention of Organ Rejection in Patients Receiving a Kidney Transplant

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2022 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up